Skip to main content

Evaluating the Automated Accellix Platform against Conventional Flow Cytometry for Cell Therapy Samples

This poster demonstrate that the Accellix Platform achieves data quality comparable to conventional methods while substantially reducing turnaround time and operational complexity.

Evaluating Accellix Against Conventional Flow Cytometry

Filename
Accellix-2026-ATW-ElevateBio-Poster.pdf
Size
751 KB
Format
application/pdf

Summary

  • The Accellix Platform demonstrated strong concordance with conventional flow cytometry across multiple PBMC lots and treatment conditions, enabling successful analysis of starting materials, in-process samples and final drug products. The platform’s FCS export capability allowed for manual review and verification when required.
  • CD-Chex Plus® control values were within Streck’s specified ranges with both inter- and intrainstrument coefficients of variation (CVs) below 10%, confirming the suitability of this control material for use with the Accellix Platform.
  • Collectively, these results support the Platform's utility for consistent, rapid, and reliable immunophenotyping in cell therapy quality control and manufacturing.

FEATURED SOLUTION

ACCELLIX™

The ACCELLIX™ Automated Cell Phenotyping Platform eliminates these limitations and automates your entire testing workflow, from sample preparation to data analysis, generating rapid cell phenotyping results directly in the collection site and/or manufacturing suite.

ACCELLIX™

Want To Discuss Your Needs? 

Complete the form below to get in touch with our team. A bioMérieux expert will be in touch using the contact information you provide. By providing your information, you agree to receive additional emails from bioMérieux about cell and gene therapy quality control.

To find out more about the management of your personal data and to exercise your rights, see our privacy policy.